Drug Trial Radar · NCT04646590
A Phase III Clinical Trial to Determine the Safety and Efficacy of ZF2001 for Prevention of COVID-19
Last checked: Nov 19, 2026Latest source record: Jan 19, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
28,904
Actual
Start
Dec 16, 2020
Primary completion
Nov 28, 2021
Study completion Dec 2022
Sponsor
- Lead sponsor
- Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Nov 30, 2020
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Prevention
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
A randomized, double-blind, placebo-controlled international multicenter clinical trial design will be adopted. A total of 29,000 subjects aged 18 years and above are planned to be recruited, including 750 subjects aged 18-59 years and 250 subjects aged 60 years and above in China; 21,000 subjects aged 18-59 years and 7,000 subjects aged 60 years and above will be recruited outside China. Safety and immunogenicity will be evaluated among the Chinese subjects, and efficacy, immunogenicity and safety will be evaluated among the subjects outside China. Among them, 750 subjects aged 18-59 and 250 subjects aged 60 and above from outside China and all subjects from China will be selected as the immunogenicity subgroup for immunogenicity bridging study. The IgG levels of SARS-COV-2 neutralizing antibody and RBD protein binding antibody will be detected by blood sampling before vaccination, 14 days and 6 months after full course of vaccination to evaluate the immunogenicity and immune persistence.
Conditions
- Prevention of COVID-19
- Safety and Efficacy
Interventions
Recombinant new coronavirus vaccine (CHO cell) groupBiological
Intramuscular injection of deltoid muscle of upper armof 25μg/0.5ml/person doseRecombinant new coronavirus vaccine (CHO cells).
Recombinant new coronavirus vaccine (CHO cells) placebo groupBiological
Intramuscular injection of deltoid muscle of upper arm of 0.5ml/person doseRecombinant new coronavirus vaccine (CHO cells) placebo.
Primary outcomes
What the sponsor says the trial is designed to measure.
- The endpoint of efficacy studyTime frame: 14 days to one year after whole vaccination
- The endpoint of safety studyTime frame: From the first dose of vaccination until 30 days after full course of vaccination
- The endpoint of safety studyTime frame: From the first dose of vaccination until 12 months after full course of vaccination
Locations
18 sites in 5 countries. Site status is shown where the registry gives one.
Hunan Provincial Center for Disease Control and Prevention
Changsha, Hunan, China
Biodimed Guayaquil Clinical Research Center
Guayaquil, Guayas, Ecuador
Biodimed Alemania Clinical Research Center
Quito, Pichincha, Ecuador
Biodimed Eloy Alfaro Clinical Research Center
Quito, Pichincha, Ecuador
Fkui-Rscm
Jakarta, Jakarta Special Capital Region, Indonesia
FK Unpad/RSHS
Bandung, West Java, Indonesia
Shaheed Zulfiqar Ali Bhutto Medical University
Islamabad, Pakistan
Aziz Fatimah Hospital
Faisalabad, Punjab Province, Pakistan
Avicenna Hospital
Lahore, Punjab Province, Pakistan
Central Park Teaching Hospital
Lahore, Punjab Province, Pakistan
National Hospital & Medical Center
Lahore, Punjab Province, Pakistan
University of Health Sciences
Lahore, Punjab Province, Pakistan
Al-Shifa Trust Eye Hospital
Rawalpindi, Punjab Province, Pakistan
Indus Hospital and Health Network
Karachi, Sindh, Pakistan
Family Hospital No.15
Tashkent, Uzbekistan
GUVD Poliklinika
Tashkent, Uzbekistan
IIV Markaziy Poliklinika
Tashkent, Uzbekistan
Toshkent viloyat IIV Poliklinika
Tashkent, Uzbekistan
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.